J&J Pledges $500m To Eliminate HIV and TB
A HIV vaccine is 'ultimate goal'
Executive Summary
The healthcare giant is investing heavily into partnerships designed to beat the two infectious diseases.
You may also be interested in...
J&J To Build Capacity, Widen Access To Bedaquiline In India
J&J ties up with agencies, Indian government to build capacity and widen access to Sirturo for TB patients.
Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions
US FDA's approval of the TB Alliance's pretomanid regimen for highly treatment-resistant tuberculosis comes with an LPAD designation and advisory committee-requested language to limit use.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.